HLS Therapeutics Inc Total Assets
HLS Therapeutics Inc total assets. Based on the latest financial reports, HLS Therapeutics Inc (HLS) holds total assets worth CA$137.28 Million CAD (≈ $99.31 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HLS Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of HLS Therapeutics Inc (1996–2025)
Total assets of HLS Therapeutics Inc from 1996 to 2025. This chart illustrates how HLS Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See HLS Therapeutics Inc (HLS) share price today for real-time trading data and today's change.
HLS Therapeutics Inc - Asset Composition Analysis
HLS Therapeutics Inc Total Assets Breakdown (December 2025)
HLS Therapeutics Inc total assets breakdown as of December 2025. HLS Therapeutics Inc's total assets of CA$137.28 Million consist of 21.2% current assets and 78.9% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 8.5% |
| Accounts Receivable | CA$7.85 Million | 5.7% |
| Inventory | CA$8.12 Million | 5.9% |
| Property, Plant & Equipment | CA$1.34 Million | 1.0% |
| Intangible Assets | CA$105.43 Million | 76.8% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore HLS Therapeutics Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HLS Therapeutics Inc's current assets represent 21.2% of total assets in 2025, a decrease from 62.1% in 1996.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 76.0% of total assets, an increase from 2.0% in 1996.
- Asset Diversification: The largest asset category is intangible assets at 76.8% of total assets.
HLS Therapeutics Inc Competitors by Total Assets
Key competitors of HLS Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
HLS Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.11 | 1.57 | 1.34 |
| Quick Ratio | 0.80 | 1.17 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$2.97 Million | CA$12.86 Million | CA$11.79 Million |
HLS Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between HLS Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.74 |
| Latest Market Cap to Assets Ratio | 0.74 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | CA$137.28 Million |
| Market Capitalization | $102.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values HLS Therapeutics Inc's assets below their book value (0.74x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HLS Therapeutics Inc's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HLS Therapeutics Inc (1996–2025)
The table below shows the annual total assets of HLS Therapeutics Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$137.28 Million ≈ $99.31 Million |
-14.15% |
| 2024-12-31 | CA$159.90 Million ≈ $115.67 Million |
-23.51% |
| 2023-12-31 | CA$209.06 Million ≈ $151.23 Million |
-13.49% |
| 2022-12-31 | CA$241.65 Million ≈ $174.81 Million |
-12.41% |
| 2021-12-31 | CA$275.90 Million ≈ $199.59 Million |
-9.21% |
| 2020-12-31 | CA$303.91 Million ≈ $219.84 Million |
-4.93% |
| 2019-12-31 | CA$319.67 Million ≈ $231.25 Million |
+4.32% |
| 2018-12-31 | CA$306.43 Million ≈ $221.66 Million |
-20.34% |
| 2017-12-31 | CA$384.65 Million ≈ $278.25 Million |
+1406.99% |
| 2016-12-31 | CA$25.52 Million ≈ $18.46 Million |
-4.04% |
| 2015-12-31 | CA$26.60 Million ≈ $19.24 Million |
-55.79% |
| 2014-12-31 | CA$60.17 Million ≈ $43.53 Million |
+9.77% |
| 2013-12-31 | CA$54.81 Million ≈ $39.65 Million |
+10.34% |
| 2012-12-31 | CA$49.68 Million ≈ $35.94 Million |
+7.97% |
| 2011-12-31 | CA$46.01 Million ≈ $33.28 Million |
+1.34% |
| 2010-12-31 | CA$45.40 Million ≈ $32.84 Million |
-15.04% |
| 2009-12-31 | CA$53.44 Million ≈ $38.66 Million |
+16.52% |
| 2008-12-31 | CA$45.86 Million ≈ $33.18 Million |
-41.20% |
| 2007-12-31 | CA$77.99 Million ≈ $56.42 Million |
+58.37% |
| 2006-12-31 | CA$49.25 Million ≈ $35.62 Million |
+11.43% |
| 2005-12-31 | CA$44.19 Million ≈ $31.97 Million |
+47.42% |
| 2004-12-31 | CA$29.98 Million ≈ $21.69 Million |
-27.75% |
| 2003-12-31 | CA$41.49 Million ≈ $30.01 Million |
+44.89% |
| 2002-12-31 | CA$28.64 Million ≈ $20.72 Million |
-5.72% |
| 2001-12-31 | CA$30.37 Million ≈ $21.97 Million |
+18.76% |
| 2000-12-31 | CA$25.58 Million ≈ $18.50 Million |
-31.91% |
| 1999-12-31 | CA$37.56 Million ≈ $27.17 Million |
+35.03% |
| 1998-12-31 | CA$27.82 Million ≈ $20.12 Million |
-32.07% |
| 1997-12-31 | CA$40.95 Million ≈ $29.62 Million |
+122.55% |
| 1996-12-31 | CA$18.40 Million ≈ $13.31 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more